Frontier Communications Joins Milestone Ultra HD Trials with SES
SES S.A. (Euronext Paris:SESG) (LuxX:SESG) today announced Frontier Communications Corporation has begun testing 4K Ultra HD content delivery using SES’s fully-managed Ultra HD distribution platform.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170226005288/en/
Frontier is the latest multichannel video programming distributor (MVPD) to join SES’s milestone trials aimed at accelerating Ultra HD delivery to homes across North America. SES has a growing number of cable and television system operators currently evaluating the satellite-based Ultra HD solution in an effort to provide the Ultra HD programming to their subscribers this year.
SES’s managed Ultra HD platform is delivered over dedicated satellite bandwidth, which provides a much higher quality viewer experience compared to current Internet-delivered 4K offerings susceptible to bottlenecks, buffering and network congestion. Currently home to nine linear Ultra HD channels, the platform provides the largest bundle of Ultra HD programming in North America.
“We are optimistic that SES’s innovative, pre-packaged Ultra HD solution will allow for a smooth transition of Ultra HD delivery to Frontier subscriber homes nationwide,” said Steve Ward, SVP of Video Technology & Content for Frontier Communications.
“MVPDs across the country have been extremely impressed with our Ultra HD channel lineup and how satellite is enabling them to leap frog to the latest transmission technologies in order to accelerate the delivery of Ultra HD to their subscriber homes,” explained Steve Corda, Vice President of Business Development for SES in North America.
Follow us on:
SES Pictures are available under http://www.ses.com/21472913/Our_Pictures
SES White papers are available under http://www.ses.com/18681915/white-papers
SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in four key market verticals (Video, Enterprise, Mobility and Government). It provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions, and businesses worldwide. SES’s portfolio includes the ASTRA satellite system, which has the largest Direct-to-Home (DTH) television reach in Europe, and O3b Networks, a global managed data communications service provider. Another SES subsidiary, MX1, is a leading media service provider and offers a full suite of innovative digital video and media services. Further information is available at: www.ses.com
Tel. +352 710 725 500
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
VERTEX-PHARMACEUTICALS19.10.2018 13:56 | pressemeddelelse
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene
TX-SCHLUMBERGER-LIMITED19.10.2018 13:02 | pressemeddelelse
Schlumberger Announces Third-Quarter 2018 Results
CA-TRADESHIFT19.10.2018 13:02 | pressemeddelelse
Tradeshift Announces Q3 2018 Results
ALIBABA-GROUP19.10.2018 12:17 | pressemeddelelse
Alibaba’s Robust Ecosystem Supercharges 2018 11.11 Global Shopping Festival
BOEHRINGER-INGELHEIM19.10.2018 12:10 | pressemeddelelse
Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum